Sumitovant Biopharma Ltd. /
Myovant Sciences Ltd.
Sumitovant Biopharma completes Myovant acquisition
- Price
- $1.7bn
- Stage
- Closed
What happened
Sumitovant Biopharma Ltd. completed its acquisition of Myovant Sciences Ltd. in an all-cash deal. The transaction value was approximately $1.7 billion.
Myovant’s shares will no longer be publicly traded and will be delisted from the New York Stock Exchange.
The source
Everything on this page comes from the source below.
Sumitovant Biopharma completes Myovant acquisition
This document is the source for the companies, stage, figure and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly